Skip to content

Study · Not a test of the peptide alone · 1989

3 results

Enhanced immune response and antitumor immunity with combinations of biological response modifiers.

Garaci E, Mastino A, Favalli C

Bulletin of the New York Academy of Medicine1 Jan 1989Cited by 9 (Europe PMC)

PMID2481523 (opens in a new tab)PMCIDPMC1807789 (opens in a new tab)PepBankPUB-02481523
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In immunosuppressed animals, combined treatment with thymosin alpha‑1 and IFN or IL-2 did not substantially modify the depressed natural killer cell response.

    In plain wordsIn animals, thymosin alpha‑1 combined with IFN or IL-2 did not clearly change the low natural killer cell response.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeNatural killer cell activity after combined thymosin alpha 1 and IFN or IL-2
    Study

    n: not reported in source

    Normal and cyclophosphamide-immunosuppressed animals; B-16 melanoma and 3LL tumor growth
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    the combined treatment does not substantially modify the depressed natural killer cell response
    1 context sentence
    Summary · context
    We have studied the effects of combination therapy with thymosin alpha 1 and IFN or IL-2 on natural killer cell activity in both normal and immunosuppressed animals after cyclophosphamide treatment and during B-16 melanoma and 3LL tumor growth.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In animals, pre-treatment with thymosin alpha‑1 before IL-2 or IFN significantly restored the boosting capacity of the two cytokines.

    In plain wordsIn animals, thymosin alpha‑1 given before IL-2 or IFN restored how well those two cytokines boost natural killer cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseRestoration of cytokine boosting of natural killer cell activity
    Study

    n: not reported in source

    Normal and cyclophosphamide-immunosuppressed animals; B-16 melanoma and 3LL tumor growth
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    thymosin alpha 1 pre-treatment significantly restores the boosting capacity of the two cytokines, IL-2 and IFN.
    1 context sentence
    Summary · context
    We have studied the effects of combination therapy with thymosin alpha 1 and IFN or IL-2 on natural killer cell activity in both normal and immunosuppressed animals after cyclophosphamide treatment and during B-16 melanoma and 3LL tumor growth.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In tumor-bearing animals treated with thymosin alpha‑1 combined with cytokines, restoration of natural killer cell activity correlated with regulation of tumor growth.

    In plain wordsIn tumor-bearing animals, regaining natural killer cell activity went together with control of tumor growth after combined treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableCorrelation of natural killer cell restoration with tumor growth regulation
    Study

    n: not reported in source

    Normal and cyclophosphamide-immunosuppressed animals; B-16 melanoma and 3LL tumor growth
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Furthermore, we have demonstrated a good correlation between restoration of natural killer cell activity and regulation of tumor growth.
    1 context sentence
    Summary · context
    We have studied the effects of combination therapy with thymosin alpha 1 and IFN or IL-2 on natural killer cell activity in both normal and immunosuppressed animals after cyclophosphamide treatment and during B-16 melanoma and 3LL tumor growth.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.